What Берлиприл 5 Treats: Main Uses and Benefits

Berlipril 5 (Enalapril Maleate) is commonly used to provide long-term, supportive management for conditions associated with acute or disruptive episodes affecting the cardiovascular system. It is applied across therapeutic domains where additional symptomatic support is needed and is relevant in contexts involving heightened systemic burden.

The medication is commonly used to help with managing Essential Hypertension (high blood pressure), assisting with managing Symptomatic Heart Failure, and managing Asymptomatic Left Ventricular Dysfunction (reduced heart pumping capacity). This approach may assist with reducing the risk of cardiovascular events, such as a stroke or heart attack.

For heart failure patients, it helps address symptom clusters related to Congestive Fluid Overload (like swelling and shortness of breath), which may contribute to easing the symptom burden and assists with maintaining functional stability during difficult episodes.

---

Quick Fact: Therapeutic Support Domains
Symptom Domains: Systemic Imbalance, Organ-specific Functional Stress, Fluid Overload
Primary Benefit: Contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

Eligibility Map: Who can and cannot use Берлиприл 5 — official regulatory information

The eligibility profile for this medicine (which contains the active substance enalapril) is strictly defined by specific exclusions, or contraindications, as documented in authoritative regulatory labeling. Use is generally allowed for adults and is approved for pediatric patients aged one month and older, provided they do not have severe kidney impairment.

---

Populations for Whom Use is Prohibited (Contraindicated)

Use of this medicine is absolutely prohibited for individuals with the following conditions or circumstances:

• Prior Angioedema: A history of angioedema (severe swelling of the face, throat, or limbs) that was related to previous treatment with any Angiotensin-Converting Enzyme (ACE) inhibitor.
• Hereditary or Idiopathic Angioedema: Having angioedema that is hereditary or has no known cause.
• Pregnancy (2nd and 3rd Trimesters): Females who are in the second or third trimesters of pregnancy. Use during the first trimester is also not recommended.
• Concurrent Drug Therapy:
  • Receiving a medicine containing aliskiren (particularly in patients with diabetes or moderate-to-severe kidney impairment).
  • Receiving a neprilysin inhibitor (e.g., sacubitril) or having taken one within the last 36 hours.
• Hypersensitivity: Known allergy or hypersensitivity to enalapril or any other ACE inhibitor.

---

Use Restrictions and Special Considerations

• Pediatric Patients: Use is not recommended for children younger than one month of age. The medicine is also strictly contraindicated for pediatric patients who have severe kidney impairment (Glomerular Filtration Rate, GFR, less than 30 mL/min/1.73m^2).
• Lactation: Use while breastfeeding is generally not recommended, and a decision must be made to discontinue either the medication or breastfeeding.
• Kidney Impairment: Requires careful dose adjustment in adults with reduced kidney function (creatinine clearance less than 80 mL/min).

Interactions with other medicines and products

Official regulatory information describes specific medicinal product categories and agents that interact with Берлиприл 5 (Enalapril), necessitating adherence to precautions and restrictions. The interaction profile is structured around combinations that pose increased risk, often due to pharmacodynamic synergism or severe pharmacokinetic effects, as documented in government regulatory labeling.

---

Interaction Scope and Constraints

Category	Regulatory Notes and Constraints
RAS Agents	Concomitant use with Aliskiren is contraindicated in diabetic patients and must be avoided in those with renal impairment. Do not use with Sacubitril/Valsartan; a 36-hour separation period is mandatory when switching.
Potassium-Related	Co-administration with potassium-sparing diuretics or potassium supplements may increase the risk of hyperkalemia.
Other Antihypertensives	Concurrent use with other antihypertensive agents or nitrates may cause a significant increase in the risk of hypotension.
NSAIDs	Use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may lead to a deterioration of renal function, especially in the elderly or volume-depleted; avoid high doses of aspirin for pain relief.
Lithium	Concomitant use with Lithium preparations may increase serum lithium levels and the risk of toxicity, requiring close monitoring.

---

Official Interaction Structure

The regulatory profile mandates that combinations classified as Contraindicated (e.g., Aliskiren in specific patients, Sacubitril/Valsartan) are strictly avoided. Other interactions require specific management, such as the discontinuation of diuretics or dose adjustments, to mitigate the risks of severe hypotension or hyperkalemia as outlined in official government documentation.

Берлиприл 5, containing the prodrug enalapril, is converted primarily in the liver by hydrolysis via carboxylesterase 1 (CES1) into its active metabolite, enalaprilat. Enalaprilat is a competitive inhibitor of the angiotensin-converting enzyme (ACE), a zinc-containing metallopeptidase found in the endothelium of blood vessels, primarily in the lungs and kidneys.

The biological target of enalaprilat is ACE, which normally catalyzes the conversion of the decapeptide angiotensin I to the octapeptide angiotensin II. By inhibiting ACE, enalaprilat blocks the production of angiotensin II, a potent endogenous vasoconstrictor and stimulator of aldosterone release. Downstream, the decrease in circulating angiotensin II reduces its interaction with the AT1 receptor on vascular smooth muscle, thereby diminishing systemic vasoconstriction. Concurrently, the inhibition of ACE decreases the degradation of bradykinin, a potent vasodilator. The combined effect of reduced angiotensin II-mediated vasoconstriction and increased bradykinin-mediated vasodilation results in a decrease in total peripheral vascular resistance. Furthermore, the diminished angiotensin II levels reduce stimulation of the adrenal cortex, leading to decreased secretion of aldosterone. This decrease in aldosterone promotes the renal excretion of sodium and water, contributing to a reduction in circulating blood volume. The system-level consequence is a modulation of the cardiovascular and renal haemodynamics.

How to Use Берлиприл 5

Берлиприл 5 (Enalapril Maleate) is an oral medication with established administration protocols. The medication is taken by mouth, and the absorption of the tablet is not significantly affected by meals, allowing it to be taken with or without food. The tablet should be swallowed whole with water.

---

Official Dosing Regimens

The established usage pattern for enalapril is characterized by initiating treatment with a low dose, followed by a titration (gradual increase) to a defined maintenance level. Dosing frequency is typically once daily for hypertension, or often twice daily (in divided doses) for heart failure and asymptomatic left ventricular dysfunction.

Indication	Typical Starting Dose	Maximum Daily Dose
Essential Hypertension	5 mg once daily	40 mg
Symptomatic Heart Failure	2.5 mg once daily or twice daily	40 mg

---

Use Protocol and Adjustments

For patients with heart failure, the dose is gradually increased over a period of two to four weeks to reach the optimal maintenance dose. Initial administration of the 2.5 mg starting dose for heart failure requires close medical supervision.

Dose adjustments are required for specific patient populations. For instance, an initial dose reduction to 2.5 mg once daily is directed for patients with impaired kidney function (creatinine clearance le 30 mL/min), and a specific 2.5 mg dose is recommended to be administered after the hemodialysis procedure on dialysis days.

Research evidence / Overview of studies for Берлиприл 5

Evidence for Use in Essential Hypertension (High Blood Pressure)

Research has primarily examined the effects of enalapril maleate, the active ingredient in Berlipril 5, in adults with high blood pressure. The study designs included numerous randomized controlled trials (RCTs) and head-to-head comparisons against other treatments, focusing on tracking outcomes monitoring physiological strain or stress by studies monitored changes in systolic and diastolic blood pressure over defined time intervals. Findings describe patterns observed in the measurement of blood pressure over short-term periods. The body of evidence related to measured changes in blood pressure in adults was studied for many years and is extensive. However, the available data for cardiovascular event outcomes may often be grouped with other medicines in the same class (ACE inhibitors).

---

Evidence for Use in Symptomatic Heart Failure

The use of enalapril in patients with symptomatic heart failure was evaluated in large-scale, placebo-controlled randomized clinical trials (RCTs). These trials focused on adults with chronic heart failure where outcomes related to systemic or functional imbalance were key concerns. Researchers primarily monitored long-term outcomes such as all-cause mortality, heart failure-specific mortality, and the frequency of hospitalization due to episodic or acute changes in the condition. Pivotal survival trials reporting changes measured in all-cause mortality and heart failure-related outcomes over multi-year observation periods. Reported findings for mortality and hospitalization rates have been broadly consistent across key, regulatory-referenced trials. While the research base is extensive for adults, data for certain groups remain insufficient.

---

What is Still Uncertain About Берлиприл 5 Research

While a significant amount of research was studied for enalapril, evidence highlights what is known—and what is still uncertain. Long-term effects are not fully established in all special populations. For instance, evidence is limited regarding its use in the youngest pediatric patients who have heart failure. In pediatric hypertension studies, data for certain groups remain insufficient, especially for infants and young children under six years of age. Furthermore, when reviewing the totality of the evidence, subgroup findings are uncertain in cases where sample sizes were modest.

Key Studies & References

1. Enalapril: Drug Information (Supports general drug class and mechanism context)
2. Effects of enalapril on mortality in severe congestive heart failure. The Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Common questions about Берлиприл 5 (FAQ)

Q: Can I take this medicine with food or should I take it on an empty stomach?

According to the official product information, Берлиприл 5 can be taken with or without food. This indicates that the presence of food in the stomach does not significantly affect how the medicine works. Patients are generally advised to maintain a consistent dosing time each day, according to their prescribing healthcare professional.

---

Q: How long will it take for the medicine to start lowering my blood pressure?

Regulatory documents indicate that the blood pressure-lowering effect typically begins about one hour after the medicine is taken. The maximum effect, meaning when the medicine is working its strongest, is usually observed within 4–6 hours. However, it may take several weeks of consistent use for the full therapeutic benefit to be achieved.

---

Q: What should I do if I forget to take a dose?

If a dose is missed, official guidance suggests taking it as soon as it is remembered. However, if the time for the next scheduled dose is near, the missed dose should generally be skipped entirely. The regulatory label cautions against taking a double dose to compensate for a missed dose, due to the increased risk of side effects.

---

Q: Can I drink alcohol while taking this medicine?

According to official product information, concurrent consumption of alcohol while using Берлиприл 5 may enhance the blood pressure-lowering effect. This interaction can potentially cause symptoms like dizziness or lightheadedness, necessitating caution. Any decisions regarding alcohol consumption should be discussed with the prescribing healthcare professional.

---

Q: Is it safe to use this medication if I have kidney problems?

Regulatory sources advise caution when considering this medicine for patients who have pre-existing kidney problems or impaired renal function. The official product information states that a lower starting dose may be necessary. Close monitoring and potential dose adjustment, based on physician assessment of the specific kidney condition, are described in the regulatory information.

---

Q: If I feel better, can I stop taking Берлиприл 5?

Official information emphasizes that treatment with Берлиприл 5 is typically long-term and must not be interrupted or discontinued without consulting a healthcare professional. Hypertension often has no noticeable symptoms, and stopping the medicine prematurely can cause blood pressure to rise again. Adherence to the prescribed treatment duration is essential, and any changes must be discussed with a healthcare provider.

---

Q: Can I take potassium supplements while on this treatment?

Regulatory documents warn against the simultaneous use of Берлиприл 5 and potassium-sparing diuretics or potassium supplements. These combinations carry a risk of significantly raising the level of potassium in the blood (hyperkalemia), which can be dangerous for heart function. Patients are advised to discuss the use of any supplements with their healthcare provider.

---

Q: Can this medication be used for children?

According to the regulatory product information, the use of Берлиприл 5 in pediatric patients is generally not recommended. There is insufficient safety data to recommend its use, particularly for patients under the age of 18. The healthcare provider is the best resource for discussing alternative, suitable treatments for children.

How to Store and Dispose of Berlipril 5

The storage and disposal of Berlipril 5 (Enalapril Maleate) tablets are governed by mandatory regulatory requirements to maintain product stability and ensure environmental safety.

Official Storage Conditions

Requirement	Official Regulatory Statement
Temperature	Do not store above 25 C and keep away from freezing.
Protection	Keep in the original container, tightly closed, and protect from moisture and excess heat.
Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Berlipril 5 must be disposed of in accordance with local, regional, and national regulations. To protect the environment, the product must not be discarded into household waste, sewers, or any body of water.